Survexins and SurvexANs - novel nano-encapsulated inhibitors of Crm1-dependent nuclear export of Survivin

Authors: Acet, Omur; Fetz, Verena; Acet, Burcu Onal; Odabasi, Mehmet; Thiermann, Raphael; Bleul, Regina; Mirzaei, Mahmoud; Knauer, Shirley K; Stauber, Roland H; Gul, Desiree

Source journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2026-11-18)

DOI: 10.1016/j.biopha.2026.120065

Abstract

The inhibitor of apoptosis protein Survivin is frequently overexpressed in many cancers. Its nuclear export signal (NES) facilitates active transport into the cytoplasm, where Survivin interferes with apoptosis and thereby promotes cancer cell survival. Thus, blocking Survivin nuclear export via the nuclear export receptor Crm1/XPO1 represents a promising anticancer strategy. We identified two novel compounds, termed "Survexins," that inhibit Crm1-mediated nuclear export exhibiting distinct inhibition kinetics and reversibility. Both compounds inhibited NES-dependent nuclear export of our model biosensors including Survivin-NES biosensor and full-length Survivin in a dose-dependent manner and induced apoptosis supporting their potential as reversible therapeutic agents. To advance their clinical potential, we encapsulated the Survexins in human serum albumin-based nanoparticles (SurvexANs), leveraging the biocompatibility and high drug-loading capacity of albumin. SurvexANs were characterized and demonstrated stable morphology, controlled particle size and surface charge, and tunable drug-release properties. Importantly, encapsulation of Survexin5 preserved its inhibitory activity and kinetic properties while providing beneficial drug-release characteristics that may enable improved control of unintended cytotoxicity. These findings provide an important contribution to the exploration of nano-formulated inhibitors of CRM1-dependent nuclear export as a potential therapeutic approach for cancer therapy.

Read the full text

Related topics

Related open access articles

Abstract and bibliographic data from PubMed (U.S. National Library of Medicine). Copyright of the abstract belongs to the original publisher or authors.